Phase II BYLieve: Alpelisib Plus Fulvestrant in PIK3CA-Mutated HR+/HER2- Advanced Breast Cancer After CDK4/6 Inhibitor Plus AI

May 29-31, 2020; Online at meetings.asco.org/am
Alpelisib plus fulvestrant demonstrated clinically meaningful efficacy based on the proportion of patients alive without PD at 6 months in this analysis of patients with PIK3CA-mutated HR+/HER2- advanced BC previously treated with CDK4/6i plus AI.
Format: Microsoft PowerPoint (.ppt)
File Size: 234 KB
Released: June 3, 2020

Acknowledgements

Provided by Clinical Care Options, LLC.

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Supported by educational grants from
GlaxoSmithKline
Merck Sharp & Dohme Corp
Novartis Pharmaceuticals Corporation

Related Content

On-demand CCO Webcast on emerging and established HER2-targeted therapies for HER2-positive early and metastatic breast cancer

On-demand CCO Webcast featuring Drs. Sara Hurvitz and Sara Tolaney on leveraging new and established treatments for HR+/HER2- advanced breast cancer

Current treatment of HER2-positive early breast cancer, including neoadjuvant and adjuvant therapy from Clinical Care Options (CCO)

Lee Schwartzberg, MD, FACP Physicians: maximum of 1.0 AMA PRA Category 1 Credit Registered Nurses: 1.0 Nursing contact hour Pharmacists: 1.0 contact hour (0.1 CEUs) Released: August 10, 2020 Expired: August 9, 2021

In this slideset from Clinical Care Options, Lee Schwartzberg, MD, FACP provides insights on the latest data on treatment for HER2-positive early breast cancer.

Lee Schwartzberg, MD, FACP Released: August 10, 2020

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.

Continue

More info

CCO’s educational programs are available completely free of charge on the ClinicalOptions.com, inPractice.com, and inPracticeAfrica.com Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?